TY - JOUR AU - Leerasiri, Pichai AU - Rattanachaiyanont, Manee AU - Angsuwathana, Surasak AU - Techatraisak, Kitirat AU - Tanmahasamut, Prasong AU - Tanphatthana, Suchada PY - 2006/05/01 Y2 - 2024/03/29 TI - Effectiveness and Safety of Very Low Dose Combined Oral Contraceptive for the Treatment of Non-atypical Endometrial Hyperplasia: A Pilot Study JF - Siriraj Medical Journal JA - Siriraj Med J VL - 58 IS - 5 SE - Original Article DO - UR - https://he02.tci-thaijo.org/index.php/sirirajmedj/article/view/245823 SP - 795-798 AB - <p><strong>Objective:&nbsp;</strong>A randomized control study to compare the effectiveness and the safety of very low dose oral contraceptive (OC) with progestin for the treatment of endometrial hyperplasia.<br><strong>Methods:&nbsp;</strong>Ten patients with non-atypical endometrial hyperplasia who did not have contraindications for OC were randomized to receive either OC (Mercilon®) or progestin (Medroxy progesterone acetate: MPA) for 6 months at the Gynecologic Endocrinology Unit, Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital. Their main measured outcomes were endometrial histopathology and adverse events.<br><strong>Results:&nbsp;</strong>Sixty percent (3 of 5) of the progestin group and 80% (4 of 5) of the OC group completed the 6-month therapy. All of them had normal endometrium by the end of the 6<sup>th</sup>&nbsp;cycle of treatment. Two cases in the progestin group and one case in the OC group withdrew from the study by the end of 1<sup>st</sup>&nbsp;cycle of treatment. No serious adverse event was detected during the study period.<br><strong>Conclusion:&nbsp;</strong>OC may be as effective and safe as progestin for the treatment of non-atypical endometrial hyperplasia.</p> ER -